The question about Breztri versus Trelegy pertains to the comparison of two commonly prescribed inhalers for managing chronic obstructive pulmonary disease (COPD). Both medications are combination therapies, but they differ in their active ingredients and approved uses.
What are the active ingredients in Breztri and Trelegy?
Breztri Aerosphere contains three active ingredients: budesonide, a corticosteroid; glycopyrrolate, a long-acting muscarinic antagonist (LAMA); and formoterol fumarate, a long-acting beta2-agonist (LABA). Trelegy Ellipta also contains three active ingredients: fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, a LAMA; and vilanterol, a LABA. [1][2]
How do Breztri and Trelegy differ in their approved uses?
Breztri is approved for the maintenance treatment of patients with COPD, including chronic bronchitis and/or emphysema, who are already receiving treatment with both budesonide and formoterol fumarate, or who are on another combination of a corticosteroid and a LABA. [1] Trelegy is approved for the maintenance treatment of patients with COPD, as a replacement therapy in adult patients with COPD who are already using fluticasone furoate and vilanterol, and a long-acting muscarinic antagonist. It is also indicated as a single inhaler triple therapy in adult patients for the regular treatment of asthma who are already receiving a combination of an ICS and a LABA plus a LAMA, and whose symptoms are inadequate or who have had exacerbations despite adequate treatment. [2]
Are there any differences in the delivery devices?
Breztri is delivered via the Aerosphere inhaler, a soft mist inhaler. Trelegy is delivered via the Ellipta dry powder inhaler. [1][2]
What do clinical studies show about the effectiveness of Breztri and Trelegy?
Studies have demonstrated that Breztri can reduce the rate of moderate or severe COPD exacerbations compared to other maintenance therapies. [1] Similarly, Trelegy has been shown to reduce the rate of moderate or severe COPD exacerbations compared to dual bronchodilator therapy or ICS/LABA therapy. [2]
What are the potential side effects of these medications?
Common side effects for Breztri include upper respiratory tract infections, pneumonia, bronchitis, oral thrush, and hoarseness. [1] For Trelegy, common side effects include pneumonia, bronchitis, upper respiratory tract infections, oral candidiasis, back pain, and arthralgia. [2]
When do the patents for Breztri and Trelegy expire?
Information regarding the specific patent expiry dates for Breztri and Trelegy can be found on DrugPatentWatch.com. [3] Patent protection is crucial for pharmaceutical companies as it grants exclusive rights to market a drug for a defined period, influencing generic competition and pricing.